141 related articles for article (PubMed ID: 21426662)
1. [Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer].
Zhang J; Qi J; Guo Y; Guo Y; Fu W; Zhou B; Wu G; Han L; He A
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):211-8. PubMed ID: 21426662
[TBL] [Abstract][Full Text] [Related]
2. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
3. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
[TBL] [Abstract][Full Text] [Related]
4. [Expression of HDGF and its implication in stage I non-small cell lung cancer].
Zhou SJ; Xu SF; Zhang HQ; Liu ZD
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):927-30. PubMed ID: 18478933
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells.
Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L
Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209
[TBL] [Abstract][Full Text] [Related]
6. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.
Eguchi R; Wakabayashi I
Oncol Rep; 2020 Jul; 44(1):14-28. PubMed ID: 32319650
[TBL] [Abstract][Full Text] [Related]
7. High Serum HDGF Levels Are Predictive of Bone Metastasis and Unfavorable Prognosis in Non-Small Cell Lung Cancer.
Zhang G; Liu Z; Chen Y; Zhang Y
Tohoku J Exp Med; 2017 Jun; 242(2):101-108. PubMed ID: 28592712
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells.
Ke Y; Zhao W; Xiong J; Cao R
FEBS Lett; 2013 Sep; 587(18):3153-7. PubMed ID: 23954293
[TBL] [Abstract][Full Text] [Related]
9. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer.
Lin YW; Li CF; Chen HY; Yen CY; Lin LC; Huang CC; Huang HY; Wu PC; Chen CH; Chen SC; Tai MH
Oral Oncol; 2012 Jul; 48(7):629-35. PubMed ID: 22361040
[TBL] [Abstract][Full Text] [Related]
10. The knockdown of LncRNA AFAP1-AS1 suppressed cell proliferation, migration, and invasion, and promoted apoptosis by regulating miR-545-3p/hepatoma-derived growth factor axis in lung cancer.
Sun J; Min H; Yu L; Yu G; Shi Y; Sun J
Anticancer Drugs; 2021 Jan; 32(1):11-21. PubMed ID: 33290312
[TBL] [Abstract][Full Text] [Related]
11. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
J Clin Oncol; 2004 Aug; 22(16):3230-7. PubMed ID: 15310766
[TBL] [Abstract][Full Text] [Related]
12. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
13. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
14. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
15. The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis.
Koh HM; Hyun CL; Jang BG; Lee HJ
Medicine (Baltimore); 2020 Dec; 99(51):e23837. PubMed ID: 33371164
[TBL] [Abstract][Full Text] [Related]
16. [Expression of hepatoma-derived growth factor and its clinical implication in stage I non-small cell lung cancer].
Zhou S; Xu S; Zhang H; Liu Z; Liang Z; Song X; Jiang Y; Zhao D
Zhongguo Fei Ai Za Zhi; 2007 Aug; 10(4):291-5. PubMed ID: 21122296
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer.
Zhao WY; Wang Y; An ZJ; Shi CG; Zhu GA; Wang B; Lu MY; Pan CK; Chen P
Biochem Biophys Res Commun; 2013 Jun; 435(3):466-71. PubMed ID: 23673296
[TBL] [Abstract][Full Text] [Related]
19. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy.
Zhao J; Ma MZ; Ren H; Liu Z; Edelman MJ; Pan H; Mao L
Clin Cancer Res; 2013 Jul; 19(13):3567-76. PubMed ID: 23695169
[TBL] [Abstract][Full Text] [Related]
20. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
